EUVIMEDEUVIMED entdecken
Crossref

Dual-tracer PET/CT and cocktail therapy with [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE in G3 Neuroendocrine Tumors (NET)

Linwei Li, Hongyin Ding, Bingyan Shen, Lingzhi Chen, Yu Zhang, Yue Chen iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026-07 · 53 (8) · 4955-4967

DOI: 10.1007/s00259-026-07833-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 17.03.2026. Verfasst von Linwei Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Octreotide, Positron Emission Tomography Computed Tomography, Organometallic Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There remains an unmet need for G3 neuroendocrine tumor (NET) treatment, and the therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) is suboptimal. PURPOSE: To investigate the feasibility and efficacy of cocktail therapy, combining co-administered [177Lu]Lu-Fibroblast activation protein (FAP) 2286 and [177Lu]Lu(lutetium)-(DOTA0, Tyr3) octreotide ([177Lu]Lu-DOTATATE), in eligible patients with G3 NET screened by dual-tracer PET/CT. METHODS: This single-center prospective study enrolled adults with histologically confirmed G3 NET (Ki67 ≥20%). Participants underwent dual-tracer PET/CT with [68Ga]Ga(gallium)-DOTATATE and [68Ga]Ga-FAP2286. Based on imaging findings, eligible participants received cocktail therapy combining co-administered [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE with a total dose of approximately 7.4 GBq per cycle. Imaging response was assessed by Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST1.0), clinical response by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), and adverse events (AEs) were graded by Common Terminology Criteria for Adverse Events (CTCAE v5.0). RESULTS: Total 23 patients (15 males, aged 52 [37-66] median [IQR]) were enrolled and 7 received 2–6 cycles of cocktail therapy. For liver metastases, [68Ga]Ga-FAP2286 exhibited a higher sensitivity (82% vs 62%) and TBRliver (4.7±2.0 vs 2.9±2.3) compared to [68Ga]Ga-DOTATATE (P=0.036). According to PERCIST 1.0, 5 participants achieved a partial metabolic response, yielding an objective response rate of 71%. The 1-year survival rate was 86%, with median overall survival and progression-free survival both exceeding 15 months. Furthermore, 71% of participants experienced an improvement in global health status. The therapy was well-tolerated, with no treatment-related deaths or Grade 3/4 adverse events. CONCLUSION: In conclusion, this prospective study demonstrates that dual-tracer PET/CT effectively identifies G3 NET patients suitable for subsequent cocktail targeted radionuclide therapy. The subsequent cocktail therapy of [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE yielded promising efficacy and safety profile. This theranostic approach represents a promising strategy for treating G3 NET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroendocrine TumorsOctreotidePositron Emission Tomography Computed TomographyOrganometallic CompoundsHumansFemaleMaleMiddle AgedAgedAdultProspective StudiesTreatment OutcomeFibroblast Activation Protein Alpha

Stichwörter der Autor:innen

Cocktail therapy·177 lutetiumDOTATATEFibroblast activation protein (FAP)Neuroendocrine Tumors

Substanzen

OctreotideOrganometallic Compoundslutetium Lu 177 dotatateFibroblast Activation Protein Alpha

Autor:innen und Institutionen

  • Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
  • Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, Sichuan , 646000, China.
  • Institute of Nuclear Medicine, Southwest Medical University, Luzhou, Sichuan, 646000, China.
  • Department of Gynecology and Obstetrics, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China.
  • Southwest Medical University, Luzhou, Sichuan Province, 646000, China.
  • Department of Nuclear Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China. zhangyu309@126.com.

ORCID-Profile: Yue Chen

Zitieren

APA

Li, L., Ding, H., Shen, B., Chen, L., Zhang, Y., & Chen, Y. (2026). Dual-tracer PET/CT and cocktail therapy with [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE in G3 Neuroendocrine Tumors (NET). European Journal of Nuclear Medicine and Molecular Imaging, 53(8), 4955-4967. https://doi.org/10.1007/s00259-026-07833-2

Vancouver

Li L, Ding H, Shen B, Chen L, Zhang Y, Chen Y. Dual-tracer PET/CT and cocktail therapy with [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE in G3 Neuroendocrine Tumors (NET). European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(8):4955-4967. doi:10.1007/s00259-026-07833-2

BibTeX
@article{Li2026,
  author = {Li, Linwei and Ding, Hongyin and Shen, Bingyan and Chen, Lingzhi and Zhang, Yu and Chen, Yue},
  title = {Dual-tracer PET/CT and cocktail therapy with [177Lu]Lu-FAP2286 and [177Lu]Lu-DOTATATE in G3 Neuroendocrine Tumors (NET)},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {8},
  pages = {4955--4967},
  doi = {10.1007/s00259-026-07833-2}
}
Kostenlos starten →